See-Saw: Challenger Natco Is Now Licensee For Lilly’s Baricitinib

 
• By Anju Ghangurde
  
see-saw
Lilly ropes in Natco as licensee for baricitinib • Source: Alamy

More from India

More from Focus On Asia